Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Expert Opinion on Investigational Drugs|June 14, 2008
Therapeutic potential of novel selective-spectrum kinase inhibitors in oncologyPatricia M Lorusso, Joseph Paul Eder
Oncology (Williston Park, N.Y.)|November 13, 2014
Prospects for targeting PD-1 and PD-L1 in various tumor typesJoseph W Kim, Joseph Paul Eder
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigenLisa A Cavacini, Mark Duval, J Paul Eder, et al.
Immunotherapy|June 29, 2016
Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitorsMaximilian Stahl, Richard Gedrich, Ronald Peck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Novel therapeutic inhibitors of the c-Met signaling pathway in cancerJoseph Paul Eder, George F Vande Woude, Scott A Boerner, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2006
Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumoursSuzanne George, Jayesh Desai, J Paul Eder, et al.
Annals of the New York Academy of Sciences|February 1, 2005
The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated regionAmanda Venti, Tony Giordano, Paul Eder, et al.
Leukemia & Lymphoma|September 13, 2006
Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906Sonali M Smith, Jeffrey L Johnson, Donna Niedzwiecki, et al.
Cancer Investigation|July 28, 2023
Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created EqualDeborah Blythe Doroshow, Wei Wei, Meenakshi Mehrotra, et al.
Cancer|December 20, 2002
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumorsM Dror Michaelson, David P Ryan, Charles S Fuchs, et al.
Pageof 4